• About Us
    • What We Do
    • Our Story
    • Board Members
    • Management Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • Media
  • Contact
  • About Us
    • What We Do
    • Our Story
    • Board Members
    • Management Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • Media
  • Contact
Palaszczuk Government boosts manufacturing capability for Ellume’s world-class COVID-19 rapid tests

Palaszczuk Government boosts manufacturing capability for Ellume’s world-class COVID-19 rapid tests

Highlights

  • Ellume receives strategic investment from Queensland State Government under Essential Goods and Supply Chain Program
  • State Government funding will enable expansion of Ellume’s Brisbane manufacturing facility, the largest of its kind in the Southern Hemisphere
  • Ellume will install multiple state-of-the-art automated production lines to speed up and enhance production capability
  • Production is already underway and Ellume is on-track to ship over 100,000 tests per day from next month, Ellume plans to manufacture and deliver 20 million Ellume COVID-19 tests within the first half of 2021

Brisbane, Australia – 8 December 2020

Digital diagnostics company Ellume today announced a strategic investment by the Queensland State Government under their $50 million Essential Goods and Supply Chain Program. The funding will allow the company to ramp up production of its range of rapid diagnostic tests for common infectious diseases, including COVID-19.  

Ellume CEO and founder Dr Sean Parsons warmly welcomed the State Government’s commitment to local manufacturing. Dr Parsons said, “Our technology is world class and the State Government’s investment boost will mean we can take our ground-breaking COVID-19 tests to the world”.

Ellume’s range of rapid diagnostic products serve to address the unprecedented global demand for fast, accurate diagnostic tests for infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus which causes COVID-19.

To meet anticipated demand, Ellume will use the State Government grant to expand its current manufacturing facility in Brisbane, already the largest of its kind in the Southern Hemisphere. The project is expected to support over 500 jobs when fully operational, with up to an additional 200 jobs created during construction.

This investment will enable the company to onshore and upscale as much of the critical component manufacturing back into Queensland as is practicable.

Ellume is on track to produce 100,000 tests per day from next month, and over 250,000 tests per day by March 2021. Ellume plans to manufacture and deliver in excess of 20 million Ellume COVID-19 tests within the first half of 2021.

Dr Parsons thanked the Premier Annastacia Palaszczuk and Treasurer Cameron Dick for supporting the company’s commitment to developing locally manufactured world-leading and life-saving diagnostics.


ENDS

InvestorsMedia & General Inquiries
Dr Sean Parsons
Founder & Managing Director
E: sean.parsons@ellumehealth.com
M: +61 7 3393 1448
Patrick Condren
Media Relations
E: patrick.condren@ellumehealth.com
M: +61 405 186 630

Recent Posts
  • BBC World Service Radio Brisbane Interview with Ellume CEO
  • FDA authorizes Ellume COVID-19 Home Test as First Over-the-Counter Fully At-Home Diagnostic Test
  • Ellume’s COVID-19 Home Test shows 96% accuracy in multi-site US clinical study
  • Palaszczuk Government boosts manufacturing capability for Ellume’s world-class COVID-19 rapid tests
  • ABC Radio “The Money” Interview with Ellume CEO, Dr Sean Parsons
Archives

ABC Radio “The Money” Interview with Ellume CEO, Dr Sean Parsons

Previous thumb

Ellume’s COVID-19 Home Test shows 96% accuracy in multi-site US clinical study

Next thumb
Scroll

ellume logo white

ABN 13 141 767 660
57 Didsbury Street,
East Brisbane, Queensland 4169
Australia

MENU

Home
About Us
COVID-19 Response
Consumer Products
Professional Products
Global Public Health Solutions
Our Tech
Media

CONTACT US

1800 001 120
+61 7 3393 1448
General Enquiries
Privacy Policy
Whistleblower Policy

Some Ellume products are pending regulatory clearance – NOT AVAILABLE FOR SALE © Ellume Limited 2020